ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In this section, we discuss the therapy of resistant CML based on BCR::ABL1 transcripts (IS) > 1% after more than one year of frontline TKI therapy, or after adequate second-line therapy at an optimal TKI dose schedule given for 3–6 months.